Based on the key indicators related to Tonix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Tonix Pharmaceuticals Holding is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Tonix Pharmaceuticals' Common Stock Shares Outstanding is relatively stable compared to the past year. As of 03/27/2025, Liabilities And Stockholders Equity is likely to grow to about 171 M, while Net Receivables is likely to drop slightly above 4.1 M. Key indicators impacting Tonix Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Tonix Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Tonix Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tonix Pharmaceuticals.
Tonix Pharmaceuticals competes with Sonnet Biotherapeutics, Palisade Bio, IBio, Common, Jaguar Animal, and Vaxart. Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Tonix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tonix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tonix Pharmaceuticals competition to find correlations between indicators driving Tonix Pharmaceuticals's intrinsic value. More Info.
Tonix Pharmaceuticals Holding is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Tonix Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tonix Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Tonix Pharmaceuticals Systematic Risk
Tonix Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tonix Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Tonix Pharmaceuticals correlated with the market. If Beta is less than 0 Tonix Pharmaceuticals generally moves in the opposite direction as compared to the market. If Tonix Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tonix Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tonix Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Tonix Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tonix Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tonix Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tonix Pharmaceuticals growth as a starting point in their analysis.
Tonix Pharmaceuticals March 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tonix Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tonix Pharmaceuticals Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on widely used predictive technical indicators. In general, we focus on analyzing Tonix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tonix Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.